Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies

Molecular Biotechnology

Volumn 53, Issue 3, 2013, Pages 326-335

  Hristodorov, Dmitrij ^a   Fischer, Rainer ^b   Joerissen, Hannah ^a   Müller Tiemann, Beate ^a   Apeler, Heiner ^a   Linden, Lars ^a  

^a BAYER PHARMA AG   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

Comparative characterization; Glycosylation; Human IgG1; Monoclonal antibody

Indexed keywords

ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITIES; BIOPHARMACEUTICALS; COMPARATIVE CHARACTERIZATIONS; DIVERSE APPLICATIONS; HUMAN IGG1; MONOCLONAL ANTIBODIES (MABS); SURFACE PLASMON RESONANCE SPECTROSCOPY; THERAPEUTIC APPLICATION;

BINDING ENERGY; CELL DEATH; DIFFERENTIAL SCANNING CALORIMETRY; ESTERIFICATION; GLYCOSYLATION; MONOCLONAL ANTIBODIES;

DISEASES;

GLYCAN; IMMUNOGLOBULIN G1 ANTIBODY;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; DIFFERENTIAL SCANNING CALORIMETRY; EXERCISE TEST; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NONHUMAN; PH; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; PROTEIN AGGREGATION; RAT; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; CALORIMETRY, DIFFERENTIAL SCANNING; CLONING, MOLECULAR; GENE EXPRESSION REGULATION; GLYCOSYLATION; HALF-LIFE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; MALE; RATS; RATS, WISTAR; SURFACE PLASMON RESONANCE;

EID: 84872496673     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-012-9531-x     Document Type: Article

References (54)

1. R Jefferis 2009 Glycosylation as a strategy to improve antibody-based therapeutics Nature Reviews Drug Discovery 8 226 234 10.1038/nrd2804 1:CAS:528:DC%2BD1MXisVShtb0%3D
2. PA McCarron, et al. 2005 Antibody conjugates and therapeutic strategies Molecular Interventions 5 368 380 10.1124/mi.5.6.9 1:CAS:528: DC%2BD28XhtFWlurw%3D
3. PJ Carter 2006 Potent antibody therapeutics by design Nature Reviews Immunology 6 343 357 10.1038/nri1837 1:CAS:528:DC%2BD28XjslOhu7o%3D
4. S Moutel F Perez 2008 Antibodies-Europe. Engineering the next generation of antibodies Biotechnology Journal 3 298 300 10.1002/biot.200800011 1:CAS:528:DC%2BD1cXkt1Cls78%3D
5. JM Reichert 2007 Trends in the development and approval of monoclonal antibodies for viral infections BioDrugs 21 1 7 10.2165/00063030-200721010-00001 1:CAS:528:DC%2BD2sXjt1Sgt70%3D
6. R Jefferis 2007 Antibody therapeutics: Isotype and glycoform selection Expert Opinion on Biological Therapy 7 1401 1413 10.1517/14712598.7.9.1401 1:CAS:528:DC%2BD2sXps1Wns7g%3D
7. IR Correia 2010 Stability of IgG isotypes in serum MAbs. 2 221 232 10.4161/mabs.2.3.11788
8. SB Hari, et al. 2010 Acid-induced aggregation of human monoclonal IgG1 and IgG2: Molecular mechanism and the effect of solution composition Biochemistry 49 9328 9338 10.1021/bi100841u 1:CAS:528:DC%2BC3cXht1OisrzN
9. T Ishikawa, et al. 2010 Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies Biological and Pharmaceutical Bulletin 33 1413 1417 10.1248/bpb.33.1413 1:CAS:528:DC%2BC3cXht1aht7bM
10. V Kayser, et al. 2011 Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies Biotechnology Journal 6 38 44 10.1002/biot.201000091 1:CAS:528:DC%2BC3MXjsVOhtw%3D%3D
11. TA Millward, et al. 2008 Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice Biologicals 36 41 47 10.1016/j.biologicals.2007.05.003 1:CAS:528:DC%2BD1cXhtV2iu7w%3D
12. MH Tao SL Morrison 1989 Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region The Journal of Immunology 143 2595 2601 1:CAS:528:DyaL1MXmtFejtrs%3D
13. CN Gamble 1966 The role of soluble aggregates in the primary immune response of mice to human gamma globulin International Archives of Allergy and Immunology 30 446 455 10.1159/000229829 1:CAS:528:DyaF2sXksFShsA%3D%3D
14. V Mett, et al. 2008 Plants as biofactories Biologicals. 36 354 358 10.1016/j.biologicals.2008.09.001
15. TG Warner 1999 Enhancing therapeutic glycoprotein production in Chinese hamster ovary cells by metabolic engineering endogenous gene control with antisense DNA and gene targeting Glycobiology 9 841 850 10.1093/glycob/9.9.841 1:CAS:528:DyaK1MXlvVWjtbs%3D
16. N Sethuraman TA Stadheim 2006 Challenges in therapeutic glycoprotein production Current Opinion in Biotechnology 17 341 346 10.1016/j.copbio.2006.06. 010 1:CAS:528:DC%2BD28XotFWltbY%3D
17. FR Schmidt 2004 Recombinant expression systems in the pharmaceutical industry Applied Microbiology and Biotechnology 65 363 372 10.1007/s00253-004- 1656-9 1:CAS:528:DC%2BD2cXotFCrtbs%3D
18. B Gasser D Mattanovich 2007 Antibody production with yeasts and filamentous fungi: On the road to large scale? Biotechnology Letters 29 201 212 10.1007/s10529-006-9237-x 1:CAS:528:DC%2BD2sXjsFOgsA%3D%3D
19. B Gasser, et al. 2006 Engineering of Pichia pastoris for improved production of antibody fragments Biotechnology and Bioengineering 94 353 361 10.1002/bit.20851 1:CAS:528:DC%2BD28XkvFWju78%3D
20. KJ Jeong SH Jang N Velmurugan 2011 Recombinant antibodies: Engineering and production in yeast and bacterial hosts Biotechnology Journal 6 16 27 10.1002/biot.201000381 1:CAS:528:DC%2BC3MXjsVOisA%3D%3D
21. D Porro, et al. 2005 Recombinant protein production in yeasts Molecular Biotechnology 31 245 259 10.1385/MB:31:3:245 1:CAS:528:DC%2BD2MXhtFygsbnL
22. ST Jung, et al. 2011 Bypassing glycosylation: Engineering aglycosylated full-length IgG antibodies for human therapy Current Opinion in Biotechnology 22 858 867 10.1016/j.copbio.2011.03.002 1:CAS:528:DC%2BC3MXhsFOhtLfJ
23. Dyson, M. R., & Durocher, Y. (2007). In M. R. Dyson and Y. Durocher (Eds.), Methods express. Bloxham: Scion Publishing Ltd.
24. LZ Benet RL Galeazzi 1979 Noncompartmental determination of the steady-state volume of distribution Journal of Pharmaceutical Sciences 68 1071 1074 10.1002/jps.2600680845 1:STN:280:DyaL3c%2FgvVOgsA%3D%3D
25. K Yamaoka T Nakagawa T Uno 1978 Statistical moments in pharmacokinetics Journal of Pharmacokinetics and Biopharmaceutics 6 547 558 1:STN:280: DyaE1M%2FptVKqtQ%3D%3D
26. MK Charter 1989 The estimation of moments: A technical note Journal of Pharmacokinetics and Biopharmaceutics 17 203 208 1:STN:280: DyaK3c%2FhtFOksw%3D%3D
27. AC Chan PJ Carter 2010 Therapeutic antibodies for autoimmunity and inflammation Nature Reviews Immunology 10 301 316 10.1038/nri2761 1:CAS:528:DC%2BC3cXltV2lu7k%3D
28. SL Sazinsky, et al. 2008 Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors Proceedings of the National Academy of Sciences of the United States of America 105 20167 20172 10.1073/pnas. 0809257105 1:CAS:528:DC%2BD1MXhsFWgtw%3D%3D
29. R Huber, et al. 1976 Crystallographic structure studies of an IgG molecule and an Fc fragment Nature 264 415 420 10.1038/264415a0 1:CAS:528:DyaE2sXhsFeksbk%3D
30. J Deisenhofer 1981 Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution Biochemistry 20 2361 2370 10.1021/bi00512a001 1:CAS:528:DyaL3MXitVKqtrc%3D
31. S Krapp, et al. 2003 Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity Journal of Molecular Biology 325 979 989 10.1016/S0022-2836(02)01250-0 1:CAS:528: DC%2BD3sXjtFGjuw%3D%3D
32. NP Bhatt K Patel RT Borchardt 1990 Chemical pathways of peptide degradation. I. Deamidation of adrenocorticotropic hormone Pharmaceutical Research 7 593 599 10.1023/A:1015862026539 1:CAS:528:DyaK3cXkslWms7s%3D
33. EY Chi, et al. 2003 Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor Protein Science 12 903 913 10.1110/ps.0235703 1:CAS:528: DC%2BD3sXjtl2jt78%3D
34. C Chumsae, et al. 2007 Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 850 285 294 10.1016/j.jchromb.2006.11.050 1:CAS:528: DC%2BD2sXkslKqtbs%3D
35. AS Rosenberg 2006 Effects of protein aggregates: An immunologic perspective AAPS Journal 8 E501 E507 10.1208/aapsj080359
36. H Schellekens 2002 Bioequivalence and the immunogenicity of biopharmaceuticals Nature Reviews Drug Discovery 1 457 462 10.1038/nrd818 1:CAS:528:DC%2BD38Xkt1Cmur8%3D
37. W Wang 2005 Protein aggregation and its inhibition in biopharmaceutics International Journal of Pharmaceutics 289 1 30 10.1016/j.ijpharm.2004.11.014 1:CAS:528:DC%2BD2MXisFKjsg%3D%3D
38. AW Vermeer CE Giacomelli W Norde 2001 Adsorption of IgG onto hydrophobic teflon. Differences between the F(ab) and F(c) domains Biochimica et Biophysica Acta 1526 61 69 10.1016/S0304-4165(01)00101-5 1:CAS:528:DC%2BD3MXisVWgur4%3D
39. DS Goldberg, et al. 2010 Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: Role of conformational and colloidal stability Journal of Pharmaceutical Sciences 100 1306 1315 10.1002/jps.22371
40. E Garber SJ Demarest 2007 A broad range of Fab stabilities within a host of therapeutic IgGs Biochemical and Biophysical Research Communications 355 751 757 10.1016/j.bbrc.2007.02.042 1:CAS:528:DC%2BD2sXisVWisr0%3D
41. MJ Feige S Walter J Buchner 2004 Folding mechanism of the CH2 antibody domain Journal of Molecular Biology 344 107 118 10.1016/j.jmb.2004.09.033 1:CAS:528:DC%2BD2cXovVKktL4%3D
42. D Ejima, et al. 2007 Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies Proteins 66 954 962 10.1002/prot.21243 1:CAS:528:DC%2BD2sXitVakuro%3D
43. V Kayser, et al. 2010 Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies Biotechnology Journal 6 38 44 10.1002/biot.201000091
44. RM Fesinmeyer, et al. 2009 Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies Pharmaceutical Research 26 903 913 10.1007/s11095-008-9792-z 1:CAS:528:DC%2BD1cXhsFamurnM
45. S Kanai, et al. 2008 Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity Journal of Pharmaceutical Sciences 97 4219 4227 10.1002/jps.21322 1:CAS:528:DC%2BD1cXht1Sgt7rE
46. S Yadav, et al. 2010 Specific interactions in high concentration antibody solutions resulting in high viscosity Journal of Pharmaceutical Sciences 99 1152 1168 10.1002/jps.21898 1:CAS:528:DC%2BC3cXmvVCrtQ%3D%3D
47. R Jefferis 2009 Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action Trends in Pharmacological Sciences 30 356 362 10.1016/j.tips.2009.04.007 1:CAS:528:DC%2BD1MXotFClsro%3D
48. SJ Lee, et al. 2002 Mannose receptor-mediated regulation of serum glycoprotein homeostasis Science 295 1898 1901 10.1126/science.1069540 1:CAS:528:DC%2BD38XhvFClt7o%3D
49. RJ Stockert 1995 The asialoglycoprotein receptor: Relationships between structure, function, and expression Physiological Reviews 75 591 609 1:CAS:528:DyaK2MXnslSlu7c%3D
50. RP Junghans CL Anderson 1996 The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor Proceedings of the National Academy of Sciences of the United States of America 93 5512 5516 10.1073/pnas.93.11.5512 1:CAS:528:DyaK28Xjt1Ojsb8%3D
51. NE Simister JC Ahouse 1996 The structure and evolution of FcRn Research in Immunology 147 333 337 10.1016/0923-2494(96)89647-7 1:CAS:528: DyaK28XlvVWhuro%3D discussion 353
52. MM Newkirk, et al. 1996 Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice Clinical and Experimental Immunology 106 259 264 10.1046/j.1365-2249.1996.d01-847.x 1:CAS:528:DyaK28XntFWrtrk%3D
53. A Wright SL Morrison 1994 Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1 Journal of Experimental Medicine 180 1087 1096 10.1084/jem.180.3.1087 1:CAS:528:DyaK2cXlsFGhtr8%3D
54. WF Dall'Acqua, et al. 2002 Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences Journal of Immunology 169 5171 5180